Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $0.9993
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 28, 26 |
| Roth Capital |
| maintain |
| Buy |
| Buy |
| Aug 18, 26 | Canaccord Genuity | maintain | Buy | Buy |
| Apr 14, 26 | Canaccord Genuity | maintain | Buy | Buy |
| Sep 30, 25 | Canaccord Genuity | maintain | Buy | Buy |
| Sep 3, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jun 9, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| May 15, 25 | Canaccord Genuity | maintain | Buy | Buy |
| Feb 10, 25 | D. Boral Capital | downgrade | Buy | Hold |
| Nov 11, 24 | D. Boral Capital | maintain | Buy | Buy |
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 34.82 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 15.43 | Oscillator | Buy |
| Williams %R (14) | -83.00 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.10 (Hist -0.00) | Oscillator | Strong Sell |
| Average Directional Index (14) | 32.34 (+DI 9.8 / -DI 24.3) | Trend | Strong Sell |
| EMA 20 | 1.10 | MA | Strong Sell |
| SMA 20 | 1.12 | MA | Strong Sell |
| EMA 50 | 1.29 | MA | Strong Sell |
| SMA 50 | 1.34 | MA | Strong Sell |
| SMA 200 | 1.98 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| May 20, 26 | Hoffman Michael B | director | P-Purchase | 54,933 @ $1.90 | $104.4K |
TTM vs. 5-year historical average (annual ratios)
| Metric | ANVS | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.6x | -4.3x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.7x | EPS est. -1.41 | Elevated |
| Price / Book | -8.8x | -0.8x | Elevated |
| Price / Sales | — | — | n/a |
| EV / EBITDA | -0.5x | -3.2x | Discount |
| Return on equity | -686.0% | — | Weak |
| Gross margin | 0.0% | 0.0% | n/a |
| Debt / Equity | 0.00 | 0.00 | Conservative |
| Piotroski / Altman Z | 1/9 | Z -18.19 | Distress |
Discounted cash flow model
| May 20, 26 |
| Hoffman Michael B |
| director |
| P-Purchase |
| 18,849 @ $1.80 |
| $33.93K |
| May 20, 26 | Hoffman Michael B | director | P-Purchase | 2,562 @ $1.75 | $4.48K |
| Apr 2, 26 | Hoffman Michael B | director | P-Purchase | 713,800 @ $2.10 | $1.50M |
| Dec 8, 25 | Hoffman Michael B | director | P-Purchase | 15,000 @ $4.24 | $63.60K |
| Dec 8, 25 | Hoffman Michael B | director | P-Purchase | 30,000 @ $4.34 | $130.2K |
| Nov 24, 25 | Hoffman Michael B | director | P-Purchase | 28,096 @ $4.15 | $116.6K |
| Nov 24, 25 | Hoffman Michael B | director | P-Purchase | 415 @ $4.14 | $1.72K |
Stock news · updated daily
MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will attend and present at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference, happening November 16-19 in Boston, MA.
MALVERN, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a collaboration with Weave Bio, an AI platform for regulatory content and knowledge management, in support of the planned New Drug Application (NDA) for buntanetap.
Annovis Bio (ANVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Annovis Bio NYSE: ANVS said it expects to report top-line results from the six-month portion of its pivotal Phase III Alzheimer's disease trial in March 2027, while preparing a rolling new drug application, or NDA, that management said could begin in May if the study meets its efficacy requirements.
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session.
MALVERN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided business updates and reported financial results for the second quarter ended June 30, 2026.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 14, 2026 | -0.45 | -0.40 | Beat 11.8% | — |
| May 15, 2026 | -0.40 | -0.63 | Miss -59.5% | — |
| Mar 16, 2026 | -0.31 | -0.39 | Miss -26.5% | — |
| Nov 12, 2025 | -0.36 | -0.37 | Miss -2.8% | — |
| Aug 12, 2025 | -0.36 | -0.32 | Beat 11.1% | — |
| May 13, 2025 | -0.47 | -0.32 | Beat 31.9% | — |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Oct 20, 2026 | 2026-10-19 19:49:30 | View |
| SC 13G/A | Oct 15, 2026 | 2026-10-15 12:34:21 | View |
| DEFA14A | Oct 7, 2026 | 2026-10-07 09:38:19 | View |
| DEF 14A | Sep 11, 2026 | 2026-09-11 16:53:49 | View |
| PRE 14A | Aug 25, 2026 | 2026-08-24 21:43:21 | View |
| 10-Q | Aug 14, 2026 | 2026-08-14 16:31:07 | View |
| 8-K | Aug 14, 2026 | 2026-08-14 16:05:42 | View |
| SC 13G | Aug 14, 2026 | 2026-08-14 12:39:30 | View |
| SC 13G | Jul 29, 2026 | 2026-07-29 16:17:16 | View |
| 8-K | Jul 10, 2026 | 2026-07-09 21:06:20 | View |
Proxy statement (DEF 14A) disclosures